Lajos Pusztai, MD
Additional treatment options are emerging for patients with HER2-positive breast cancer, according to Lajos Pusztai, MD.
, Pusztai, a professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discussed neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.
OncLive: What data do we have supporting neoadjuvant therapy for patients with HER2-positive breast cancer?
HER2-positive disease has become rich in treatment options, which sometimes creates confusion with how to best select treatments for patients. In the neoadjuvant setting, combining trastuzumab, pertuzumab (Perjeta), and a third-generation chemotherapy of paclitaxel followed by doxorubicin hydrochloride (Adriamycin) and cyclophosphamide (AC) or AC followed by paclitaxel and either of the targeted therapies, produces pathologic complete response (pCR) rates of 75% to 80% in the estrogen receptor (ER)-negative subset and 50% to 60% in the ER-positive subset. Current therapies can accomplish high pCR rates.
... to read the full story